Emcure Pharmaceuticals Limited’s initial public offering of Equity Shares to open on July 03, 2024

Emcure Pharmaceuticals Limited (the “Company”) proposes to open its initial public offering of Equity Shares (“Offer”) on Tuesday, July 02, 2024. The Anchor Investor Bid/Offer Period is one Working Day prior to Bid/Offer Opening Date, that is, Wednesday, July 03, 2024. Bid/ Offer Closing Date will be on Friday, July 05, 2024. The Price Band of the Offer has been fixed from ₹ 960 per Equity Share to ₹ 1008 per Equity Share. Bids can be made for a minimum of 14 Equity Shares and multiples of 14 Equity Shares thereafter.  
 

Emcure Pharmaceuticals Limited has announced an initial public offering of up to ₹10 equity shares for cash at a price of ₹10 per equity share, including a share premium. The offer includes a fresh issue of ₹8,000.00 million equity shares by the company (the "Fresh Issue") and an offer for sale of ₹11,428,839 equity shares. The offer includes 420,000 equity shares by Satish Ramanlal Mehta, 1,268,600 by Namita Vikas Thapar, 10,000 by Samit Satish Mehta, 40,000 by Sunil Rajanikant Mehta, 7,234,085 by BC Investments IV Limited, 1,342,586 by the promoter group selling shareholders, 300,000 by Arunkumar Purshotamlal Khanna, and 813,568 by other selling shareholders. The offer for sale includes the Promoter Selling Shareholders, Promoter Group Selling Shareholders, Individual Selling Shareholder, and Investor Selling Shareholders. The offer for sale is collectively referred to as the "Offer for Sale."

The company offers up to 108,900 equity shares of face value of ₹10 each, aggregating up to ₹[●] million, for subscription by eligible employees. The company also provides a discount of up to ₹90 per equity share to eligible employees bidding under the Employee Reservation Portion. The Net Offer and the Offer constitute ●]% and ●]% of the post-Offer paid-up equity share capital respectively.

The Offer is made through the Book Building Process, following Rule 19(2)(b) of the SCRR and Regulation 31 of the SEBI ICDR Regulations. The Company may allocate up to 50% of the Net Offer to Qualified Institutional Buyers (QIBs) proportionately, with up to 60% allocated to Anchor Investors discretionarily. One-third of this portion is reserved for domestic Mutual Funds, subject to valid bids received at or above the Anchor Investor Allocation Price. If under-subscription or non-allocation occurs, the balance Equity Shares of face value of ₹10 each will be added to the remaining QIB Portion. 5% of the Net QIB Portion is available for allocation proportionately to Mutual Funds, while the rest is available for all QIBs (other than Anchor Investors) subject to valid bids received at or above the Offer Price. A minimum of 15% of the Net Offer is available for Non-Institutional Bidders, with one-third reserved for bidders with application sizes of more than ₹0.20 million and up to ₹1.00 million. A minimum of 35% of the Net Offer is available for Retail Individual Bidders.

The Red Herring Prospectus offers Equity Shares to be listed on both BSE and NSE. Kotak Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private Limited, and J.P. Morgan India Private Limited are Book Running Lead Managers. Capitalized terms in this press release have the same meaning as in the RHP.